Skip to main content
JAMA Network logoLink to JAMA Network
. 2024 Mar 14;150(6):530. doi: 10.1001/jamaoto.2024.0317

Errors in Table 2

PMCID: PMC10941014  PMID: 38483368

In the Original Investigation titled “Lead Time to Recurrence After Posttreatment Plasma and Saliva HPV DNA Testing in Patients With Low-Risk HPV Oropharynx Cancer,”1 published online on July 27, 2023, and in the September 2023 print issue, there were errors in Table 2. The row labeled “HPV DNA assay completed” should be “HPV DNA assay completed post treatment,” the row “Post treatment” should be “Salivary rinse + plasma,” the row “Salivary rinse + plasma” should be “Plasma only,” and the row “Plasma only” should be “Salivary rinse only.” This article was corrected online.

Reference

  • 1.Califano J, Yousef A, Mostafa H, et al. Lead time to recurrence after posttreatment plasma and saliva HPV DNA testing in patients with low-risk HPV oropharynx cancer. JAMA Otolaryngol Head Neck Surg. 2023;149(9):812-819. doi: 10.1001/jamaoto.2023.1730 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from JAMA Otolaryngology-- Head & Neck Surgery are provided here courtesy of American Medical Association

RESOURCES